Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146403 · ClinicalTrials.gov registry record · Phase 2
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Phase 2 study, sponsored by Genocea Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03146403 is a Phase 2 study that was terminated before completion, run by Genocea Biosciences. The registered enrollment target is 33 participants.
The verdict
NCT03146403, a Phase 2 study, was terminated before completion, sponsored by Genocea Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
Interventions
- BIOLOGICAL Matrix-M2
- BIOLOGICAL GEN-003
- OTHER 0.9% normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-05-24 |
| Est. Completion | 2018-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03146403
The ClinicalTrials.gov registry entry for NCT03146403 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genocea Biosciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matrix-M2 is the first listed.
NCT03146403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03146403 about?
NCT03146403 is a clinical study titled "Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection". The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
What is the current status of trial NCT03146403?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-05-24. Estimated completion is 2018-06-11.
What interventions are being tested in trial NCT03146403?
The interventions under investigation include: Matrix-M2 (BIOLOGICAL), GEN-003 (BIOLOGICAL), 0.9% normal saline (OTHER).
Who is sponsoring clinical trial NCT03146403?
This trial is sponsored by Genocea Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.